Healthcare Industry News: flow diversion
News Release - January 6, 2010
ev3 Announces Completion of Voluntary RecallPLYMOUTH, Minn., Jan. 6 --(HSMN NewsFeed)-- ev3 Inc. (Nasdaq:EVVV ) today announced that a voluntary Class I recall of the TrailBlazer Support Catheter was completed in December 2009, and all affected units are in the company's possession.
No other ev3 devices were involved in this action. In December, ev3 launched a redesigned TrailBlazer Support Catheter that is currently available globally.
About ev3 Inc.
Since its founding in 2000, ev3 has been dedicated to developing innovative and breakthrough technologies for the endovascular treatment of peripheral vascular and neurovascular diseases. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today -- plaque excision systems, peripheral angioplasty balloons, stents, embolic protection devices, liquid embolics, embolization coils, flow diversion devices, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at http://www.ev3.net.
ev3, the ev3 logo and TrailBlazer are trademarks of ev3 Inc. and its subsidiaries, registered in the U.S. and other countries.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.